Relation Therapeutics, a London, UK-based biotechnology company leveraging computational and experimental approaches to drug discovery, raised $35M in Seed funding.
The round, which brought the total amount to $60M, was led by DCVC and NVentures, with participation from initial seed lead Magnetic Ventures, existing investors Khosla Ventures, and Abcam founder Jonathan Milner, and new investors ARK Invest and Deerfield Management Company.
The company intends to use the funds to advance its osteoporosis pipeline towards the clinic, as well as initiate discovery campaigns in new therapeutic areas of high unmet need.
Led by CEO David Roblin, Relation Therapeutics is a biotechnology company discovering and developing transformational medicines, with experimental and computational systems at its core. Its Lab-in-the-Loop approach combines single cell multi-omics directly from patient tissue, functional assays and machine learning to understand the biological processes in human health and disease. The company is advancing programs using insights from its technology and data, starting with bone-related diseases.
As a first indication, Relation is developing treatments for osteoporosis. As part of these efforts, Relation has built considerable proprietary data resources, including Osteomics, a clinical observational study to create a large functional, single-cell bone atlas derived from human patient tissue.
FInSMEs
15/03/2024